A tier · strong
Cabergoline has strong randomised and comparative evidence for normalising prolactin in hyperprolactinaemia, superior to bromocriptine, but its valvulopathy and impulse-control signals meaningfully qualify the grade.
cabergoline
Cabergoline is a long-acting ergoline dopamine D2 agonist approved for hyperprolactinaemic disorders, where randomised comparison shows it normalises prolactin more reliably and is better tolerated than bromocriptine. Its principal safety concerns are dose-related cardiac valvulopathy, first identified in Parkinson's disease populations, and dopaminergic impulse-control disorders.
the explanation
Cabergoline mimics dopamine at the pituitary, which switches off prolactin production, and it is an approved treatment for high prolactin levels. The main worries are heart valve damage, especially at the much higher doses once used in Parkinson's disease, and compulsive behaviours such as gambling or hypersexuality.
regulatory status
Approved prescription medicine
FDA-approved 23 December 1996 for hyperprolactinaemic disorders, idiopathic or due to pituitary adenomas. Approved in some jurisdictions as adjunctive therapy in Parkinson's disease and for lactation suppression. The Dostinex brand has been discontinued in the US while generic cabergoline remains available. Not approved for prolactin management alongside androgen or peptide use.
how it works · proposed mechanism
Cabergoline activates pituitary dopamine D2 receptors, which tonically inhibit prolactin release.
Lactotroph D2 agonism
Dopamine is the physiological brake on prolactin secretion. Cabergoline binds lactotroph D2 receptors with high affinity, suppressing prolactin synthesis and release and shrinking prolactin-secreting adenomas.
Prolonged pituitary residence
Cabergoline's 63-69 hour half-life and slow dissociation give sustained receptor occupancy well beyond plasma clearance. This underlies its twice-weekly dosing schedule in clinical practice.
Off-target 5-HT2B agonism
As an ergoline, cabergoline also activates serotonin 5-HT2B receptors on cardiac valve interstitial cells. This drives fibroblast proliferation and valve leaflet thickening, the mechanism behind the valvulopathy signal.
what’s reported
evidence shape
26 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Cabergoline's approved evidence base is about correcting a documented pathological state, hyperprolactinaemia from a pituitary adenoma or idiopathic cause, in patients under endocrine follow-up with echocardiographic surveillance where indicated. Using it off-label to suppress prolactin alongside androgen or peptide use is an entirely different proposition: there are no randomised trials in that setting, no baseline pathology to correct, no cardiac monitoring, and the valvulopathy and impulse-control signals documented in supervised populations apply in full.
key published findings
- Human trial (registration data, Dostinex US label): prolactin normalisation was achieved in 29%, 76%, 74% and 95% of patients across ascending twice-weekly dose groups in a placebo-controlled trial.
- Human trial (comparative trial versus bromocriptine, NEJM 1994 and US label): prolactin normalised in 77% of cabergoline-treated patients versus 59% on bromocriptine, with discontinuation for adverse events in 2% versus 6%.
- Observational (Zanettini et al., NEJM 2007): in Parkinson's disease patients, cabergoline and pergolide were associated with a significantly increased frequency of clinically important valvular regurgitation compared with controls and with non-ergot dopamine agonists, in a dose-related pattern.
- Meta-analysis (JCEM 2019, 13 case-control studies, 836 cabergoline-treated hyperprolactinaemia patients vs 1,388 controls): treatment for 12 months or more was associated with moderate or severe tricuspid regurgitation at OR 3.74 (95% CI 1.79-7.8, P<0.001) and mild tricuspid regurgitation at OR 1.91 (95% CI 1.28-2.87, P=0.002), with no significant increase in other valvulopathies and no case diagnosed on clinical symptoms.
- Regulatory data (Dostinex US label): common adverse effects include nausea 27-29%, headache 26% and dizziness 15-17%; the label warns that pathological gambling, increased libido and hypersexuality have been reported and are generally reversible on dose reduction.
limitations of the evidence
- The strongest valvulopathy evidence comes from Parkinson's disease populations exposed to substantially higher cumulative doses than those used for hyperprolactinaemia, so risk at lower exposure is extrapolated rather than directly established.
- The tricuspid regurgitation signal in hyperprolactinaemia is echocardiographic; the JCEM meta-analysis noted that no patient was diagnosed on the basis of clinical symptoms, leaving clinical significance uncertain.
- Impulse-control disorder data in hyperprolactinaemia are largely cross-sectional and prospective observational rather than randomised, and detection depends heavily on active screening.
documented safety signals
- Cardiac valvulopathy: the central safety concern, with a clear dose-related signal in Parkinson's disease populations (Zanettini, NEJM 2007) attributed to 5-HT2B agonism on valve fibroblasts; post-marketing cases are noted in US labelling, particularly with long-term high-dose use.
- Tricuspid regurgitation in hyperprolactinaemia at lower doses: OR 3.74 (95% CI 1.79-7.8) for moderate or severe disease after 12 months or more of treatment in a 13-study meta-analysis, though none was clinically symptomatic.
- Impulse-control disorders including pathological gambling, compulsive shopping, binge eating, increased libido and hypersexuality; documented in prolactinoma cohorts and named in US labelling, generally reversible on dose reduction or withdrawal.
- Fibrotic complications beyond the heart, including pleural effusion, pulmonary fibrosis and retroperitoneal fibrosis with prolonged administration.
- Nausea (27-29%), headache (26%), dizziness (15-17%), constipation and fatigue are common.
- Orthostatic hypotension, particularly on initiation, and syncope.
- Somnolence and sudden-onset sleep episodes, a class effect of dopamine agonists with implications for driving.
- Psychiatric effects including hallucinations, confusion, psychotic symptoms, mania and, on withdrawal, a dopamine agonist withdrawal syndrome with anxiety, depression and dysphoria.
- Contraindicated in uncontrolled hypertension, in a history of pulmonary, pericardial or retroperitoneal fibrotic disorders, and in a history of cardiac valvular disorders on echocardiography.
- Suppressing prolactin in someone without documented hyperprolactinaemia has no established benefit and removes a hormone with physiological roles, while retaining the full serotonergic and dopaminergic risk profile.
identity
| full name | Cabergoline |
| category | Ancillary & Endocrine |
| modality | small molecule |
| formula | C26H37N5O2 |
| molar mass | 451.6 g/mol |
| cas | 81409-90-7 |
| half-life | Approximately 63-69 hours; reported at 79-115 hours in patients with pituitary tumours |
laboratory handling
| storage | Tablets stored at controlled room temperature, approximately 20-25 degrees C, protected from light in the manufacturer's container. |
| solubility | White crystalline powder, soluble in ethanol, chloroform and DMSO, and only slightly soluble in water; solubility improves in acidic aqueous media. |
| co-studied with | Discussed off-label for prolactin-related effects associated with androgen or 19-nor compound use, but no randomised trial has evaluated it in that context and the valvulopathy and impulse-control signals documented in supervised patient populations are not eliminated by using it without indication. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedUS prescribing information · 2024 · official
Sigma-Aldrich product data · 2024 · official
New England Journal of Medicine · 2007 · observational
Journal of Clinical Endocrinology and Metabolism · 2019 · reviews
New England Journal of Medicine · 1994 · randomized
Journal of Clinical Endocrinology and Metabolism · 2019 · observational
others in Ancillary & Endocrine